Hello, Fool! | Login | Signup | My Fool
Aug 20, 2008 3:38 PM ET | Site Changes | Help
A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
View Ticker Page (ARNA)
Results 1 - 10 of 66 : 12345Next »
Recs
Manifest (85.76) Submitted: 12/29/06 1:14 PM : Start Price: $13.67 ARNA Score: -43.27
This one is SPECULATIVE. And in keeping with David Gardner's recent confession about the source of investing ideas, I'll come clean with where this one comes from. I have a friend who is a pharmaceutical scientist and fellow investment educator. (...
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
ImRichBeotch (< 20) Submitted: 3/28/08 1:02 AM : Start Price: $7.70 ARNA Score: -12.50
Currently in the prescription weight loss market patients have 2 options: Xenical or Meridia. Xenical blocks fat absorption in the gut by blocking an enzyme that breaks long chain fatty acids into smaller pieces (thus blocking the ability of the gut...
Report this Post Replies: 3 | Reply | Permalink
jkrm93 (< 20) Submitted: 11/09/06 1:48 PM : Start Price: $15.04 ARNA Score: -49.63
This stock is going higher in the long run. It is going to hang with the market for the next few months until news on its trial. If all goes as expected, that news is going to boost the stock towards its price targets.
skat5 (99.41) Submitted: 6/23/07 1:37 PM : Start Price: $11.13 ARNA Score: -28.01
Very risky! However, it represents an alternative to the CB-1 antagonists big pharmas have been backing, one of which was recently resoundingly rejected by the FDA for causing suicidal thoughts (well, that's dieting for you!). The slim (ok, I'll sto...
6tables (93.37) Submitted: 12/26/07 12:06 PM : Start Price: $8.05 ARNA Score: -7.21
analyze this on a risk to reward basis and it is a potential big winner
biojimkent (43.35) Submitted: 6/19/08 12:41 AM : Start Price: $4.76 ARNA Score: 37.36
Among the publicly traded small biotechs, this has the most promising looking anti-obesity drug that I know of. The dose-response curves on their stage 2 clinical trials are totally pretty. Unless they were faked (and I haven't _seen_ any evidence ...
1DLE (< 20) Submitted: 1/24/07 10:33 AM : Start Price: $12.95 ARNA Score: -40.12
Two Blockbusters in the pipeline.
sweetwilliam3 (< 20) Submitted: 3/02/07 4:31 PM : Start Price: $11.88 ARNA Score: -39.10
The 5HT2b selective agonist certainly looks promising in phase IIb trials. It demonstrates significant efficacy in terms of helping patients lose weight w/ an acceptable side effect profile. This was demonstrated on a particlualrly hard to tx. grou...
downwithpumpers (99.83) Submitted: 11/02/07 4:39 AM : Start Price: $9.91 ARNA Score: -20.34
With the recent raising of 109 million in cash completed maybe this company finally can realize a little of its potential. Just maybe.
boater9384 (< 20) Submitted: 2/21/08 9:51 AM : Start Price: $7.07 ARNA Score: -3.91
Short-term call for now; see how the diet pill does, looking for a bounceback.